Interobserver agreement for the detection of optical coherence tomography features of neovascular age-related macular degeneration.
暂无分享,去创建一个
[1] J. R. Landis,et al. The measurement of observer agreement for categorical data. , 1977, Biometrics.
[2] C. Toth,et al. Optical coherence tomography reader agreement in neovascular age-related macular degeneration. , 2007, American journal of ophthalmology.
[3] William J Feuer,et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. , 2007, American journal of ophthalmology.
[4] C. Lantz,et al. Behavior and interpretation of the κ statistic: Resolution of the two paradoxes , 1996 .
[5] C. Regillo,et al. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. , 2007, American journal of ophthalmology.
[6] L. da Cruz,et al. Repeatability of stratus optical coherence tomography measures in neovascular age-related macular degeneration. , 2008, Investigative ophthalmology & visual science.
[7] Gerald Liew,et al. Ranibizumab for neovascular age-related macular degeneration. , 2007, The New England journal of medicine.
[8] Maciej Wojtkowski,et al. Ophthalmic imaging by spectral optical coherence tomography. , 2004, American journal of ophthalmology.
[9] Susan Schneider,et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.
[10] C. Lantz,et al. Behavior and interpretation of the kappa statistic: resolution of the two paradoxes. , 1996, Journal of clinical epidemiology.
[11] A. Viera,et al. Understanding interobserver agreement: the kappa statistic. , 2005, Family medicine.
[12] C. Bunce,et al. A randomised, double-masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age-related macular degeneration: clinical trial design , 2008, Trials.